




- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *C07K 16/46* (2006.01)
- (21) **International Application Number:**
PCT/IB2022/052645
- (22) **International Filing Date:**
23 March 2022 (23.03.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/165,416 24 March 2021 (24.03.2021) US
- (71) **Applicant: JANSSEN BIOTECH, INC.** [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US).
- (72) **Inventors: BEDNAR, Kyle;** 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **KUMAR, Naresh;** 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **SINGH, Sanjaya;** 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **GANESAN, Rajkumar;** 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **YANG, Danlin;** 1400 McKean Road, Spring House, Pennsylvania 19477 (US).
- (74) **Agent: SHIRTZ, Joseph F.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** ANTIBODY TARGETING CD22 AND CD79B



(57) **Abstract:** Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*